» Tolerx Initiates Dosing Of Otelixizumab, A Novel Type 1 Diabetes Agent, In DEFEND, A Phase 3 Clinical Trial
Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, announced the initiation of a pivotal Phase 3 clinical trial that…